{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-067446","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.816536+00:00","generated_at":"2026-06-01T06:55:16.272745+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Century Therapeutics reports Phase 1 ELiPSE-1 data: 30% CRR, 40% ORR in R/R NHL; no DLTs","bullets":["As of March 27, 2024, 12 patients evaluable for safety; no DLTs or GvHD observed; most cycles outpatient.","Across all dose levels (10 evaluable), 30% complete response rate and 40% objective response rate.","At Schedule A dose levels 300M and 1B cells, 40% CRR and 60% ORR in 5 heavily pre-treated patients.","Novel cfDNA assay suggests CNTY-101 persists in tissues; AUC trends with dose.","Dose escalation continues at DL3B (3 weekly infusions of 1B cells) and DL4A (single 3B cells)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-067446","json":"https://secwatch.observer/filing/0001104659-24-067446.json","markdown":"https://secwatch.observer/filing/0001104659-24-067446.md","text":"https://secwatch.observer/filing/0001104659-24-067446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924067446/0001104659-24-067446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924067446/tm2416244d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:55:16.272745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}